TYPE OF CYP450 2C19 GENE METABOLIZERS IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION IN THE REPUBLIC OF NORTH MACEDONIA -A PILOT STUDY
Clopidogrel has an antiplatelet effect, which is used to reduce the risk of myocardial infarction and stroke in high-risk patients in the context of primary prophylaxis. In the body it is subjected to metabolism by the liver enzyme system CYP450. In this project, laboratory conditions have been established to determine the polymorphisms of the CYP450 2C19 gene. The structure of the polymorphisms in the CYP450 2C19 gene and the type of metabolizer has been determined.This study included 42 heart patients with St. post PCI, mean age 65-9.7 years, treated with 75 mg Clopidogrel daily. The following polymorphisms were examined: c.681G> A; c.636G> A; c.1A> G; c.1297C> T; c.395G> A; c.819 + 2T> A; c.358T> C; c.-806C> T. Appropriate laboratory conditions have been established for the precise determination of polymorphisms in the CYP450 2C19 gene and the determination of the type of metabolizer. The results showed that in our patients the largest number of polymorphisms occur at the position c.681G> A which leads to the creation of an intermediate metabolizer, while the polymorphism at the position c.-806C> T leads to the creation of an ultrafast metabolite. The largest number of polymorphisms occurs in c.681G> A CYP450 2C19 gene, which leads to the creation of an intermediate metabolizer. Because of this, and before starting the therapy in patients St. post PCI, it is necessary to first determine what clopidogrel metabolizers they are and whether they possess LF or GF alleles.
Key words: clopidogrel, metabolite, polymorphisms, CYP450 2C19 gene.
2. Dean L. Clopidogrel Therapy and CYP2C19 Genotype. 2012 Mar 8 [Updated 2018 Apr 18]. In: Pratt VM, Scott SA, Pirmohamed M, et al., editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-.Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/
3. Boiten W. Annex I. Hydrometry. 2003;1–50.
4. Yang Y, Lewis JP, Hulot JS, et al. The pharmacogenetic control of antiplatelet response: Candidate genes and CYP2C19. Expert Opin Drug Metab Toxicol. 2015;11(10):1599–617.
5. Comin J, Kallmes D. Pharmacology vignette: Clopidogrel (plavix). Am J Neuroradiol. 2011;32:2002–4.
6. Marian AJ. Cytochrome p-450 polymorphisms and response to clopidogrel. Curr Atheroscler Rep. 2009;11(3):157–60.
7. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295.
8. Savi P, Nurden P, Nurden AT, et al. Clopidogrel: A review of its mechanism of action. Platelets. 1998;9(3–4):251–5.
9. Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine. Front Genet. 2013;3:1–7.
10. Díaz-Villamarín X, Dávila-FajardoCL, Martínez-González LJ, et al. Genetic polymorphisms influence on the response to clopidogrel in peripheral artery disease patients following percutaneous transluminal angioplasty Pharmacogenomics. 2016; 17(12):1327-38. doi: 10.2217/pgs-2016-0056
11. Chan NC, Eikelboom JW, Ginsberg JS, et al. Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood. 2014;124(5):689–99.
12. https://www.pharmvar.org/gene/CYP2C19. Last accessed 12.05.2022
13. Scott SA, Sangkuhl K, Stein CM, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317–23.
14. Yi X, Wang Y, Lin J, et al. Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates with Efficacy of Clopidogrel and Adverse Events on Patients with Ischemic Stroke. Clin Appl Thromb. 2017;23(7):761–8.
15. Li-Wan-Po A, Girard T, Farndon P, et al. Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C19*17. Br J Clin Pharmacol. 2010;69(3):222–30.
16. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-reduced-effectiveness-plavix-clopidogrel-patients-who-are-poor. Last accessed 12.05.2022
17. Spiroski M, Arsov T, Petlichkovski A, et al. Case Study: Macedonian Human DNA Bank (hDNAMKD) as a source for public health Genetics. In: Health Determinants in the Scope of New Public Health. Ed. by Georgieva L, Burazeri G. Hans Jacobs Company: Sofia, 2005:33-44.
18. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-857.
19. Price MJ, Murray SS, Angiolillo DJ, et al; GIFT Investigators. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol. 2012;59(22):1928-1937
20. Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913-958.
21. Lewis JP, Stephens SH, Horenstein RB, et al. The CYP2C19*17 variant is not independently associated with clopidogrel response. J Thromb Haemost. 2013;11(9):1640-1646.
22. Aradi D, Komocsi A, Price MJ, et al. Tailored Antiplatelet Treatment Study Collaboration. Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. Int J Cardiol 2013; 167:2140–2148.
23. Jiang M, You JHS. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. Pharmacogenetics and Genomics 2015; 25:609–617.